FDA Drug Labeling Services
This guide explains FDA drug labeling requirements for OTC drugs (Drug Facts panel) and prescription drugs (Prescribing Information), the SPL submission process, OTC monograph compliance, misbranding, Medication Guides, and what FDA Registration Assistance does for drug labeling clients.
OTC Drug Facts Panel vs. Prescription Drug Prescribing Information — Two Completely Different Formats
OTC Drug Facts Panel Required Sections Under 21 CFR 201.66
Prescription Drug PI Sections Under 21 CFR 201.56 and 201.57
OTC Drug Monographs and the Misbranding Consequences of Non-Compliance
What Is an OTC Drug Monograph?
An OTC drug monograph is the FDA’s regulatory rulebook for a specific OTC drug category — defining the permitted active ingredients, required indications, mandatory warning language, and required directions. Common monographs: Antacid Drug Products (21 CFR Part 331); External Analgesics; Topical Antifungal (21 CFR Part 333); Sunscreen (21 CFR Part 352). A product complying fully with an applicable monograph can be marketed without a separate NDA. Products outside any monograph — or not complying fully — require an approved NDA to be legally marketed.
Misbranding Under FD&C Act Section 502
A drug is misbranded when: its labeling is false or misleading (502(a)); required label information is missing (502(b), 502(e), 502(f)); adequate directions for use are absent (502(f)(1)); adequate warnings are missing (502(f)(2)); a prescription drug lacks the “Rx only” statement; or the Drug Facts panel is missing, incorrectly formatted, or incomplete for OTC drugs. Distributing a misbranded drug in interstate commerce is a prohibited act under 21 U.S.C. § 331. Consequences: Warning Letters, import refusal under FD&C Act Section 801(a), recall, seizure, and injunction.
FDA Drug Labeling Services — What We Review and Prepare
OTC Drug Facts Panel
Review and preparation of OTC Drug Facts panels for compliance with 21 CFR 201.66: section order; required language from the applicable OTC monograph; font size compliance; inactive ingredient alphabetical order; adequate warnings; correct Directions section by population. Identification of any monograph non-compliance.
Prescription Drug PI Review
Review of prescription drug Prescribing Information for compliance with 21 CFR 201.56 and 201.57: required section presence and order; Highlights accuracy and length; Boxed Warning format if present; Adverse Reactions table structure; Patient Counseling Information completeness; and consistency with the approved NDA/ANDA labeling.
SPL Labeling Submission
Preparation and submission of SPL drug labeling documents for eDRLS drug product listings. Full PI or Drug Facts content structured in HL7 XML with correct FDA section codes. Coordination of label changes with eDRLS listing updates to maintain consistency between physical labels and FDA regulatory databases.
OTC Monograph Compliance
Assessment of OTC drug products against applicable monographs. Identification of active ingredients and claims not covered by any monograph (requiring NDA). Review of Drug Facts language for exact monograph compliance — paraphrase of required monograph language is not permitted.
Misbranding Risk Assessment
Assessment of drug labels against all misbranding provisions of FD&C Act Section 502. Identification of: false or misleading claims; missing required information; inadequate directions for use; missing warnings; missing “Rx only” statement; non-compliant Drug Facts format. Written report of gaps and corrective actions.
Medication Guide and REMS
Review of Medication Guide requirements under 21 CFR Part 208 for applicable Rx drugs. Advice on REMS labeling implications where the drug is subject to a Risk Evaluation and Mitigation Strategy. Coordination with Patient Counseling Information section of the PI.
Need FDA Drug Labeling Compliance Support?
FDA Registration Assistance provides professional drug labeling services for OTC and prescription drug manufacturers worldwide — Drug Facts panel review and preparation, Prescribing Information review, SPL labeling document preparation and submission, OTC monograph compliance assessment, misbranding risk assessment, and coordination with eDRLS drug establishment registration and drug listing. 1,000+ clients. 135+ countries. 15+ years of FDA regulatory experience.
Contact us at info@fdaregistrationassistance.com or call +1 (928) 275-8333.
Frequently Asked Questions — FDA Drug Labeling
1. What are the FDA drug labeling requirements under 21 CFR Part 201?
21 CFR Part 201 requires: name and place of business (201.1); net quantity of contents (201.51); active ingredient declaration (201.10); adequate directions for use (201.5, unless exempt); adequate warnings (201.6); and for OTC drugs, the Drug Facts panel format (201.66). Prescription drugs must follow the full Prescribing Information format under 21 CFR 201.56 and 201.57. Labels that don’t comply are misbranded under FD&C Act Section 502.
2. What is the Drug Facts panel and what are its required sections?
Required under 21 CFR 201.66 for all OTC drugs. Required sections in order: Active ingredient(s)/amount; Purpose; Uses; Warnings (Do not use; Ask a doctor; Ask a doctor or pharmacist; When using; Stop use; If pregnant or breast-feeding); Directions; Other information; Inactive ingredients; Questions? Minimum font size: 6-point for most text; 8-point for “Drug Facts” title. All language must match the applicable OTC monograph verbatim.
3. What are the prescription drug labeling requirements under 21 CFR 201.56 and 201.57?
Required sections include: Highlights of Prescribing Information (one-page maximum); full PI Table of Contents; Boxed Warning (if FDA-required); Indications and Usage; Dosage and Administration; Dosage Forms and Strengths; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Overdosage; Description; Clinical Pharmacology; Nonclinical Toxicology; Clinical Studies; How Supplied/Storage; Patient Counseling Information. Full PI submitted as SPL through eDRLS.
4. What is Structured Product Labeling (SPL) for drug labeling?
SPL is the HL7 XML format used by FDA for drug labeling submissions. The full label content is embedded in the SPL XML with FDA-defined section codes (e.g., 34066-1 for Boxed Warning, 34067-9 for Indications and Usage). SPL is submitted through eDRLS as part of the drug product listing. Physical label and SPL must match. See the eDRLS Drug Registration Guide.
5. What is an OTC drug monograph?
An OTC drug monograph establishes the permitted active ingredients, permitted indications, required warnings, and required Drug Facts labeling language for a specific OTC drug category. Antacid (21 CFR Part 331), topical antifungal (21 CFR Part 333), sunscreen (21 CFR Part 352). A product complying fully with an applicable monograph can be marketed without a separate NDA. Products outside any monograph require an approved NDA.
6. When is a drug considered misbranded under FDA regulations?
A drug is misbranded under FD&C Act Section 502 when: labeling is false or misleading (502(a)); required information is missing (502(b), (e), (f)); adequate directions for use are absent (502(f)(1)); adequate warnings are absent (502(f)(2)); a Rx drug lacks the “Rx only” statement; or the Drug Facts panel is missing, wrongly formatted, or incomplete. Distributing a misbranded drug is a prohibited act under 21 U.S.C. § 331.
7. What is a Medication Guide and when is it required?
A Medication Guide (MedGuide) is FDA-approved patient labeling required for certain high-risk prescription drugs under 21 CFR Part 208 — where FDA determines labeling alone is insufficient for safe use. Required when: the drug has serious risks affecting the patient’s decision to use it; or patient adherence to instructions is critical to avoid serious adverse reactions. Must be distributed with every dispensed unit by pharmacies.
8. What is the relationship between drug labeling and eDRLS drug product listings?
Drug product listings submitted through eDRLS must include the drug’s labeling in SPL format. The SPL labeling and the physical label must match. When labeling changes, the eDRLS drug listing must be updated with the revised SPL labeling. FDA Registration Assistance coordinates drug labeling review and update with eDRLS drug listing updates.
9. What are the most common FDA drug labeling violations?
Missing or incorrectly formatted Drug Facts panel on OTC drugs (wrong section order, missing sections, non-compliant font sizes); drug claims on products marketed as foods or supplements; Rx drug marketed without “Rx only” statement; missing or inadequate directions for use; missing “Do not use” warnings; SPL labeling not matching the physical label; and OTC monograph non-compliance (using claims or active ingredients not permitted by the monograph).
10. What is adequate directions for use for OTC drugs?
Under 21 CFR 201.5, adequate directions means a layperson can use the drug safely for its intended purpose. Must include: dosage for each intended use; frequency; duration; any special handling; and contraindicated populations (age restrictions, pregnancy warnings). The Drug Facts Directions section must provide complete dosage information for adults and, where applicable, separate pediatric dosing.
11. What is a Boxed Warning (Black Box Warning)?
A Boxed Warning is required in the Prescribing Information of prescription drugs where FDA has determined the drug carries a risk of serious adverse reactions that are life-threatening or cause severe disability. Appears at the top of the PI in a box format. Included in the Highlights of Prescribing Information. Not all Rx drugs have a Boxed Warning — only when FDA determines it is necessary for patient safety.
12. Do private label OTC drug distributors need drug labeling compliance?
Yes. A private label distributor whose name appears on an OTC drug label is the responsible firm for labeling compliance under 21 CFR 201.1. Must ensure the Drug Facts panel is compliant, active ingredient claims are covered by an applicable OTC monograph or approved NDA, and the label meets all 21 CFR Part 201 requirements. The contract manufacturer’s labeling compliance does not transfer to the distributor.
13. How does FDA drug labeling differ for generic drugs (ANDAs) vs. brand-name drugs (NDAs)?
Generic drug labeling (ANDA) must be the same as the Reference Listed Drug (RLD) labeling — with modifications limited to those FDA permits. Generic manufacturers cannot change indications, dosing, or warnings from the RLD without prior FDA approval. Brand-name drug labeling (NDA) is developed as part of the NDA submission and approved by FDA before marketing. Label changes to approved NDA drugs require supplements (PAS, CBE-30, or CBE-0) depending on the nature of the change.
14. What are FDA drug labeling requirements for foreign manufacturers?
Foreign drug manufacturers exporting to the United States must ensure drug labels comply with all applicable FDA drug labeling requirements including Drug Facts format (21 CFR 201.66) for OTC drugs and full PI format (21 CFR 201.56/201.57) for Rx drugs. Labels must include English translations of all required information. Non-compliant labels trigger misbranding citations and import refusal under FD&C Act Section 801(a).
15. What is the Drug Facts panel font size requirement?
Under 21 CFR 201.66: most text minimum 6-point type; “Drug Facts” title minimum 8-point type in bold. If the label is too small to accommodate the full Drug Facts panel at minimum type sizes, the entire label must be redesigned or the product must use a panel extension (leaflet). Font size non-compliance is a common drug labeling deficiency.
16. What is the difference between OTC drug labeling and dietary supplement labeling?
OTC drug: Drug Facts panel (21 CFR 201.66); standardized OTC monograph language; mandatory warnings; no DSHEA disclaimer. Dietary supplement: Supplement Facts panel (21 CFR Part 101.36); DSHEA disclaimer; structure/function claims (not disease claims). A product with disease claims is a drug and requires Drug Facts labeling. Wrong panel type on either = misbranding.
17. What happens if an OTC drug label does not comply with the applicable monograph?
An OTC drug not complying with the applicable monograph is misbranded and may also be an unapproved new drug. The monograph’s required language for uses, warnings, and directions must be used verbatim — paraphrasing is not permitted. FDA can issue Warning Letters, detain imports, and seize products for monograph non-compliant labeling.
18. Does FDA Registration Assistance help with drug label changes and updates?
Yes. FDA Registration Assistance helps with drug label changes — reviewing updated label content for 21 CFR Part 201 compliance; coordinating label changes with eDRLS drug listing updates in SPL format; advising on whether a change requires a prior approval supplement or changes-being-effected supplement; and ensuring physical label revisions match the SPL drug listing.
19. What are REMS programs and how do they affect drug labeling?
REMS (Risk Evaluation and Mitigation Strategies) are FDA-required programs for high-risk drugs where labeling alone cannot manage serious safety risks. REMS can include Medication Guides, communication plans for healthcare providers, and elements to assure safe use (ETASU) such as required prescriber training or dispensing restrictions. REMS are incorporated into the approved Prescribing Information and must be referenced in the Patient Counseling Information section.
20. How does drug labeling relate to drug advertising?
Drug advertising for prescription drugs is regulated under 21 CFR Part 202 — requiring fair balance of benefits and risks and consistency with approved labeling. OTC drug advertising is subject to FTC oversight in addition to FDA labeling requirements. Any claim in drug advertising must be consistent with the claims permitted in the FDA-approved labeling. Claims beyond the approved labeling constitute off-label promotion.
21. What is the adequate warnings requirement for OTC drug labeling?
Under 21 CFR 201.66, the Warnings section must include in order: “Do not use” (absolute contraindications); “Ask a doctor before use if you have” (relative contraindications); “Ask a doctor or pharmacist before use if you are” (drug interactions); “When using this product” (side effects); “Stop use and ask a doctor if” (adverse reaction signals); “If pregnant or breast-feeding” (reproductive safety). Required subsections and language taken from the applicable OTC monograph. Missing or out-of-order warning subsections = misbranding under 502(f)(2).
22. What FDA drug labeling services does FDA Registration Assistance provide?
OTC Drug Facts panel review and preparation (21 CFR 201.66); Rx Prescribing Information review (21 CFR 201.56/201.57); SPL labeling document preparation and eDRLS submission; OTC monograph compliance assessment; misbranding risk assessment (FD&C Act Section 502); Medication Guide compliance review; drug label change coordination with eDRLS listing updates. 1,000+ clients. 135+ countries.
23. How does drug labeling for homeopathic products differ?
Homeopathic drug products are subject to FDA drug regulations. FDA’s 2020 risk-based enforcement policy (Guidance for Industry: Drug Products Labeled as Homeopathic) replaced the 1988 CPG. Homeopathic product labeling must include active ingredients (homeopathic nomenclature), intended uses, directions, and warnings. Products for serious conditions or high-risk populations receive higher enforcement priority.
24. How does FDA Registration Assistance help foreign drug manufacturers with labeling?
For foreign drug manufacturers: drug labeling review against 21 CFR Part 201 requirements; SPL labeling preparation and submission through eDRLS; U.S. Agent services; drug establishment registration; OTC monograph compliance; and misbranding risk assessment. 1,000+ clients. 135+ countries. 15+ years of FDA regulatory experience.
25. How do I get started with FDA drug labeling compliance support?
Contact FDA Registration Assistance at info@fdaregistrationassistance.com or call +1 (928) 275-8333. Provide your drug product name and type (OTC or Rx), current label or label artwork files, applicable OTC monograph (if any) or NDA/ANDA number, and any specific compliance questions. FDA Registration Assistance will assess your labeling against 21 CFR Part 201 requirements and provide actionable compliance guidance.
